Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune checkpoint inhibitors in patients with brain metastasis from NSCLC, RCC, and melanoma.
Authors
Adam Lauko
Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Adam Lauko, Bicky Thapa, Xuefei Jia, Manmeet Singh Ahluwalia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 214)
DOI
10.1200/JCO.2018.36.5_suppl.214
Abstract #
214
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.
First Author: Clara Allayous
Poster
2023 ASCO Annual Meeting
Immune-related adrenal insufficiency: A single center retrospective analysis.
First Author: Natalya Polshina
Poster
2022 ASCO Annual Meeting
Better (a little) late than never: The impact of steroidal treatment initiation timing on the outcome of patients with melanoma treated with immunotherapy.
First Author: Nethanel Asher
Poster
2021 ASCO Annual Meeting
Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Early results from a multicenter phase I trial.
First Author: Shearwood McClelland III